Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Cancer Patients
NCT04038619Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in diarrhea and Colitis, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of fecal microbiota transplantation (FMT)-related adverse events at 3 months and Clinical response/remission of immune-related diarrhea/colitis at 2 weeks. Started Feb 2021; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
diarrheaColitis
Beyond the preview
Go deeper on NCT04038619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038619.